Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
36.4M
-
Number of holders
-
10
-
Total 13F shares, excl. options
-
33.1K
-
Shares change
-
+19.7K
-
Total reported value, excl. options
-
$983K
-
Value change
-
+$585K
-
Number of buys
-
4
-
Number of sells
-
-1
-
Price
-
$29.70
Significant Holders of Rapport Therapeutics, Inc. - Common Stock, $0.001 par value (RAPP) as of Q3 2025
10 filings reported holding RAPP - Rapport Therapeutics, Inc. - Common Stock, $0.001 par value as of Q3 2025.
Rapport Therapeutics, Inc. - Common Stock, $0.001 par value (RAPP) has 10 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 33.1K shares
of 36.4M outstanding shares and own 0.09% of the company stock.
Largest 10 shareholders include Voya Investment Management LLC (13.3K shares), CATALYST PRIVATE WEALTH, LLC (10K shares), SG Americas Securities, LLC (6.27K shares), Belvedere Trading LLC (3.73K shares), CWM, LLC (1.46K shares), NISA INVESTMENT ADVISORS, LLC (1.35K shares), GAMMA Investing LLC (354 shares), SIGNATUREFD, LLC (205 shares), Rise Advisors, LLC (50 shares), and Global Retirement Partners, LLC (45 shares).
This table shows the top 10 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.